Aelis Farma SA Market Cap ($11.79 Million)
Market Cap & Net Worth: Aelis Farma SA (AELIS)
Aelis Farma SA market cap. Aelis Farma SA (PA:AELIS) has a market capitalization of $11.79 Million (€10.09 Million) as of November 6, 2026. Listed on the PA stock exchange, this France-based company holds position #26483 globally and #445 in its home market, demonstrating a 13.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aelis Farma SA's stock price €0.74 by its total outstanding shares 13632242 (13.63 Million). Also see Aelis Farma SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Aelis Farma SA Market Cap History (2022–2026)
Aelis Farma SA market cap history from 2022 to 2026. Data shows change from $215.79 Million to $11.79 Million (-45.21% CAGR). Check Aelis Farma SA stock quote for real-time trading data and today's change.
Index Memberships
Aelis Farma SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$265.66 Billion | 0.00% | #30 of 36 |
Weight: Aelis Farma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aelis Farma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aelis Farma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Aelis Farma SA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.90x
Aelis Farma SA's market cap is 11.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $215.79 Million | $3.81 Million | -$14.29 Million | 56.65x | N/A |
| 2023 | $208.78 Million | $9.05 Million | -$5.08 Million | 23.06x | N/A |
| 2024 | $31.88 Million | $2.68 Million | -$7.46 Million | 11.90x | N/A |
Competitor Companies of AELIS by Market Capitalization
Companies near Aelis Farma SA in the global market cap rankings as of November 6, 2026. Also see Aelis Farma SA balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Aelis Farma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Aelis Farma SA (2022–2026)
Market capitalization of Aelis Farma SA from 2022 to today. Between 2022 and today, Aelis Farma SA's market cap moved from $215.79 Million to $ 11.79 Million, with a yearly change of -45.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.79 Million | -34.22% |
| 2025 | €17.93 Million | -43.75% |
| 2024 | €31.88 Million | -84.73% |
| 2023 | €208.78 Million | -3.25% |
| 2022 | €215.79 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Aelis Farma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.79 Million USD |
| MoneyControl | $11.79 Million USD |
| MarketWatch | $11.79 Million USD |
| marketcap.company | $11.79 Million USD |
| Reuters | $11.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more